Quinupristin-dalfopristin is active against Toxoplasma gondii

Synercid and each of its components (quinupristin and dalfopristin) were examined for their activities against Toxoplasma gondii. In vitro, intracellular replication of tachyzoites was inhibited by synercid and each of its two components. The 50% inhibitory concentrations of synercid, quinupristin,...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 1999-08, Vol.43 (8), p.2043-2045
Main Authors: KHAN, A. A, SLIFER, T. R, ARAUJO, F. G, REMINGTON, J. S
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - pharmacology
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Cells, Cultured
Dose-Response Relationship, Drug
Drug Combinations
Female
Fibroblasts
Humans
Medical sciences
Mice
Pharmacology. Drug treatments
Susceptibility
Toxoplasma - drug effects
Toxoplasma - growth & development
Toxoplasma gondii
Toxoplasmosis, Animal - drug therapy
Virginiamycin - analogs & derivatives
Virginiamycin - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Synercid and each of its components (quinupristin and dalfopristin) were examined for their activities against Toxoplasma gondii. In vitro, intracellular replication of tachyzoites was inhibited by synercid and each of its two components. The 50% inhibitory concentrations of synercid, quinupristin, and dalfopristin were 1.6, 2.7, and 6.3 microg/ml, respectively. Thus, synercid was markedly more active than its components. Treatment of acutely infected mice with 100 or 200 mg of synercid per kg of body weight per day administered intraperitoneally for 10 days resulted in survival of 50% (P = 0.0002) and 100% (P < 0.0001) of infected mice, respectively, whereas all control mice died by day 18. In contrast, treatment with 200 mg of either quinupristin and dalfopristin per kg per day alone resulted in only 20% survival; treatment with 50 mg of either drug per kg per day resulted only in the prolongation of time to death. These results suggest that synercid may be useful for treatment of toxoplasmosis in humans.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.43.8.2043